doi:j.critrevonc

First Page		Document Content
Date: 2007-05-09 10:30:53 Growth factors Tyrosine kinase receptors Proteins Angiogenesis inhibitors Vascular endothelial growth factor VEGF receptors Receptor tyrosine kinase Angiogenesis Platelet-derived growth factor Biology Cell biology Angiology		doi:j.critrevonc Add to Reading List Source URL: www.brimr.org Download Document from Source Website File Size: 964,19 KB Share Document on Facebook

	References [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC DocID: 1qSc2 - View Document
	Technology Opportunity, Ref. No. UZNovel nanomolar inhibitor of Eph tyrosine kinases New small molecule inhibitors of Eph kinases have been developed which have potential therapeutic application in angiogenesis DocID: 1p0SG - View Document
	1st line treatment: what has changed in the last 2 years? 10th European International Kidney Cancer Symposium Lyon April 2015 DocID: 19YWa - View Document
	My ideal bevacizumab patient? Bernard Escudier Institut Gustave Roussy, Villejuif, France Ninth European International Kidney Cancer Symposium Dublin – 25-26 April 2014 DocID: 19RpI - View Document
	doi:j.critrevonc DocID: 18qC5 - View Document